The MMRF’s 2025 Donor Impact Report Highlights Bold Bets, Breakthrough Data, and Groundbreaking Trials

The Multiple Myeloma Research Foundation® (MMRF®) continues to drive the most innovative, patient-centered research in multiple myeloma—all thanks to the MMRF community’s extraordinary generosity.

In 2025, our supporters enabled us to invest $27.1 million in critical research and patient education programs that are making a meaningful impact and accelerating cures.

The MMRF is proud to share its 2025 Donor Impact Report.

Here’s a preview of what our supporters made possible last year:

• Through the Myeloma Investment Fund®, we made strategic investments in two companies pursuing in vivo CAR T-cell therapy platforms, which promise to make this therapy more accessible and affordable.
• The Horizon Clinical Trials program—run by the Multiple Myeloma Research Consortium® (MMRC®), a subsidiary of the MMRF—moved full speed ahead and surpassed many of its goals.
• MMRF data powered several of the field’s major developments, and we launched our next innovation in data-sharing: the MMRF Virtual Lab^TM.
• Our trusted patient education and support programs reached more than 17,000 patients and caregivers.
• …and so much more.

“Myeloma’s biggest breakthroughs—and cures—are within reach, but the road ahead demands our greatest effort yet,” said the MMRF’s President and CEO Michael Andreini. “With the MMRF’s supporters by our side, we’re ready to meet any challenge.”

Read the full 2025 Donor Impact Report here.